Track Perspective Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Perspective Therapeutics Inc. Common Stock CATX · Stock Open Perspective Therapeutics Inc. Common Stock in new tab

0.9431 USD
EPS
-1.25
P/B
0.37
ROE
-45.86
Beta
1.99
Target Price
9.71 USD
Loading chart...
Key Metrics
Earnings dateMarch 15, 2027
EPS-1.25
Book Value2.58
Price to Book0.37
Debt/Equity1.25
% Insiders8.837%
Growth
Revenue Growth-0.90%
Estimates
Forward P/E-0.91
Forward EPS-1.03
Target Mean Price9.71

DCF valuation

Model fair value for Perspective Therapeutics Inc. Common Stock (CATX)
Result
Sign in to run the valuation for CATX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
14 analysts · consensus Strong buy · mean target 9.71 USD (low 4.00, high 15.00) · as of 15 Nov 2026
Low 4.00
Mean 9.71
High 15.00
Price 0.9431
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Perspective Therapeutics Inc. Common Stock Logo Perspective Therapeutics Inc. Common Stock Analysis (CATX)

United States Health Care Official Website Stock

Is Perspective Therapeutics Inc. Common Stock a good investment? Perspective Therapeutics Inc. Common Stock (CATX) is currently trading at 0.9431 USD. Market analysts have a consensus price target of 9.71 USD. This suggests a potential upside from current levels.

Earnings Schedule: Perspective Therapeutics Inc. Common Stock is expected to release its next earnings report on March 15, 2027. The market consensus estimate for Forward EPS is -1.03.

Investor FAQ

Does Perspective Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Perspective Therapeutics Inc. Common Stock?

Perspective Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 15, 2027. The company currently has a trailing EPS of -1.25.

Company Profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Exchange Ticker
ASE (United States) CATX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
June 17, 2024 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion